Sign in Subscribe
Pharmaceutical industry

Tradjenta Tablets Now Available by Prescription in the United States

Strategic Insights

— 2 min read

Tradjenta, a new prescription medication used in conjunction with diet and exercise to lower blood sugar in adults with type 2 diabetes, is now available at pharmacies across the country, including Walgreens, CVS, Rite Aid, and many chain and independent pharmacies. The U.S. Food and Drug Administration (FDA) approved Tradjenta on May 2 as a treatment for type 2 diabetes. Patients with type 1 diabetes or diabetic ketoacidosis should not take Tradjenta, as it has not been studied in combination with insulin. "The rapid availability of Tradjenta for adults with type 2 diabetes following FDA approval is a testament to Boehringer Ingelheim and Lilly's joint commitment to improving patient care," said Wa'el Hashad, vice president, cardiovascular and metabolic disorders, Boehringer Ingelheim Pharmaceuticals, Inc.

Key Takeaways:

  • Tradjenta tablets are now available by prescription in pharmacies across the United States, including major chains and independent pharmacies.
  • The FDA approved Tradjenta on May 2 as a treatment for type 2 diabetes used in conjunction with diet and exercise.
  • Tradjenta should not be used in patients with type 1 diabetes or diabetic ketoacidosis, as it has not been studied in combination with insulin.
  • Boehringer Ingelheim and Lilly are in active discussions with insurance companies to secure formulary coverage for Tradjenta at a co-pay level similar to other preferred branded products.
  • Wa'el Hashad, vice president of cardiovascular and metabolic disorders at Boehringer Ingelheim Pharmaceuticals, emphasized the importance of patient care in the development and accessibility of Tradjenta.
  • Tradjenta is an important new treatment option for the millions of Americans living with type 2 diabetes.

Statistics:

  • May 2: The FDA approved Tradjenta as a treatment for type 2 diabetes.
  • Millions of Americans: The approximate number of people living with type 2 diabetes in the United States.
  • 1 dose to remember: The simplicity of Tradjenta dosing, as emphasized by Wa'el Hashad.
  • Preferred branded products: The target co-pay level being sought by Boehringer Ingelheim and Lilly for Tradjenta formulary coverage.

Sources:

  • "Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced Tradjenta (linagliptin) tablets are now available by prescription in pharmacies across the United States..." [1]
  • "The U.S. Food and Drug Administration (FDA) approved Tradjenta on May 2, as a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes." [1]
  • "Wa'el Hashad, vice president, cardiovascular and metabolic disorders, Boehringer Ingelheim Pharmaceuticals, Inc. 'The health of patients is our first priority and we work diligently to ensure our medications are accessible for patients...'" [1]
  • Tradjenta website: www.Tradjenta.com

Read more